Interactions between Shiga toxins and human polymorphonuclear leukocytes

Human intestinal infections by Shiga toxin (Stx)‐producing Escherichia coli cause hemorrhagic colitis and hemolytic uremic syndrome (HUS), which represents the main cause of acute renal failure in early childhood. In HUS, Stx released in the gut enter the bloodstream and are targeted to renal endothelium. The mechanism of toxin delivery is still a matter of debate, although the role of polymorphonuclear leukocytes (PMN) as a Stx carrier has been indicated. The aim of this paper was to better define the interactions between Stx and human PMN. Direct and indirect flow cytometric analysis and binding experiments with radiolabeled toxins demonstrated that Stx bind to the surface of human mature PMN but not to immature PMN from G‐CSF‐treated donors. The use of the human myeloid leukemia cell (HL‐60) model for inducible cell differentiation confirmed that the toxin binding occurs only after granulocytic differentiation. Stx binding caused a delay of the spontaneous apoptosis of PMN, as shown by the delayed appearance of apoptotic nuclei and activation of caspase 3 and by the higher number of cells negative to the annexin V‐binding assay after 48 h. Moreover, flow cytometric analysis of mixed Stx‐positive and Stx‐negative PMN populations showed that the toxins were transferred from positive to negative PMN. The delayed, spontaneous apoptosis and the passage of the toxic ligand from older PMN to new, mature cells entering the circulation from the bone marrow may explain the previously reported persistence of Stx in the blood of children with HUS.

[1]  P. Marcato,et al.  Differential binding of Shiga toxin 2 to human and murine neutrophils. , 2007, Journal of medical microbiology.

[2]  L. P. Van den Heuvel,et al.  Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  P. Sestili,et al.  Molecular Damage and Induction of Proinflammatory Cytokines in Human Endothelial Cells Exposed to Shiga Toxin 1, Shiga Toxin 2, and α-Sarcin , 2007, Infection and Immunity.

[4]  C. Chalk,et al.  Comparative Analysis of the Abilities of Shiga Toxins 1 and 2 To Bind to and Influence Neutrophil Apoptosis , 2006, Infection and Immunity.

[5]  A. Edefonti,et al.  Shiga Toxins Present in the Gut and in the Polymorphonuclear Leukocytes Circulating in the Blood of Children with Hemolytic-Uremic Syndrome , 2006, Journal of Clinical Microbiology.

[6]  P. Tazzari,et al.  Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study , 2005, Bone Marrow Transplantation.

[7]  B. Deurs,et al.  Delivery into cells: lessons learned from plant and bacterial toxins , 2005, Gene Therapy.

[8]  P. Tarr,et al.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome , 2005, The Lancet.

[9]  D. E. Olins,et al.  The mechanism of granulocyte nuclear shape determination: possible involvement of the centrosome. , 2005, European journal of cell biology.

[10]  A. Caprioli,et al.  Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome , 2004, Cytometry. Part B, Clinical cytometry.

[11]  G. Frankel,et al.  Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture , 2004, Cellular microbiology.

[12]  P. Marcato,et al.  Serum Amyloid P Component Binding to Shiga Toxin 2 Requires Both A Subunit and B Pentamer , 2003, Infection and Immunity.

[13]  F. Gunzer,et al.  Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. , 2003, Blood.

[14]  A. Edefonti,et al.  Shiga Toxin–Producing Escherichia coli Infections Associated with Hemolytic Uremic Syndrome, Italy, 1988–2000 , 2003, Emerging infectious diseases.

[15]  L. Barbieri,et al.  Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells 1 , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  T. Takeda,et al.  Serum Amyloid P Component Is the Shiga Toxin 2-neutralizing Factor in Human Blood* , 2001, The Journal of Biological Chemistry.

[17]  D. Acheson,et al.  Shiga Toxin Translocation across Intestinal Epithelial Cells Is Enhanced by Neutrophil Transmigration , 2001, Infection and Immunity.

[18]  L. V. D. Heuvel,et al.  Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. , 2001, Journal of the American Society of Nephrology : JASN.

[19]  D. Moulding,et al.  Molecular control of neutrophil apoptosis , 2001, FEBS letters.

[20]  T. Takeda,et al.  Escherichia coli Shiga toxin. , 2000, Journal of natural toxins.

[21]  V. V. van Hinsbergh,et al.  Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. , 2000, Blood.

[22]  D. E. Olins,et al.  Retinoic acid differentiation of HL-60 cells promotes cytoskeletal polarization. , 2000, Experimental cell research.

[23]  H. Kondo,et al.  Inhibition of Neutrophil Apoptosis by Verotoxin 2 Derived from Escherichia coli O157:H7 , 1999, Infection and Immunity.

[24]  L. Barbieri,et al.  A rapid and sensitive method to measure the enzymatic activity of ribosome-inactivating proteins. , 1998, Nucleic acids research.

[25]  James C. Paton,et al.  Pathogenesis and Diagnosis of Shiga Toxin-Producing Escherichia coli Infections , 1998, Clinical Microbiology Reviews.

[26]  D. Acheson,et al.  Translocation of Shiga toxin across polarized intestinal cells in tissue culture , 1996, Infection and immunity.

[27]  V. V. van Hinsbergh,et al.  Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. , 1996, Blood.

[28]  F. Lund-Johansen,et al.  Expression of cell surface antigens during the differentiation of HL-60 cells induced by 1,25-dihydroxyvitamin D3, retinoic acid and DMSO. , 1995, Leukemia research.

[29]  E. Huberman,et al.  Glycosphingolipid patterns in human promyelocytic HL-60 leukemia cells susceptible or resistant to differentiation induction by phorbol 12-myristate 13-acetate. , 1993, Biochimica et biophysica acta.

[30]  N. Taniguchi,et al.  Total metabolic flow of glycosphingolipid biosynthesis is regulated by UDP-GlcNAc:lactosylceramide beta 1-->3N-acetylglucosaminyltransferase and CMP-NeuAc:lactosylceramide alpha 2-->3 sialyltransferase in human hematopoietic cell line HL-60 during differentiation. , 1992, The Journal of biological chemistry.

[31]  A. Caprioli,et al.  Hemolytic-Uremic Syndrome and Vero Cytotoxin-Producing Escherichia coli Infection in Italy , 1992 .

[32]  A. Caprioli,et al.  Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. The HUS Italian Study Group. , 1992, The Journal of infectious diseases.

[33]  R. Tauxe,et al.  The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. , 1991, Epidemiologic reviews.

[34]  R. Petras,et al.  Escherichia coli 0157:H7-associated colitis: A clinical and histological study of 11 cases , 1990 .

[35]  T G Cotter,et al.  HL‐60 cells induced to differentiate towards neutrophils subsequently die via apoptosis , 1990, Clinical and experimental immunology.

[36]  J Kelly,et al.  The Colonic Pathology of Escherichia coli 0157: H7 Infection , 1990, The American journal of surgical pathology.

[37]  R. Petras,et al.  Escherichia coli O157:H7-associated colitis. A clinical and histological study of 11 cases. , 1990, Gastroenterology.

[38]  L. Blomberg,et al.  Purification of Shiga toxin by α‐d‐galactose‐(1 → 4)‐β‐d‐galactose‐(1 → 4)‐ β‐d‐glucose‐(1 →) receptor ligand‐based chromatography , 1989 .

[39]  L. Becker,et al.  The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. , 1988, Human pathology.

[40]  J. H. Green,et al.  Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies , 1988, Infection and immunity.

[41]  M. Cassatella,et al.  Interferon-gamma activates human neutrophil oxygen metabolism and exocytosis. , 1988, Immunology.

[42]  T. Yutsudo,et al.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. , 1988, European journal of biochemistry.

[43]  S. Collins,et al.  The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. , 1987, Blood.

[44]  C. Pai,et al.  The histopathology of rectosigmoid biopsies from adults with bloody diarrhea due to verotoxin-producing Escherichia coli. , 1987, American journal of clinical pathology.

[45]  H. Lior,et al.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. , 1985, The Journal of infectious diseases.

[46]  F. Takaku,et al.  Characteristic expression of glycosphingolipid profiles in the bipotential cell differentiation of human promyelocytic leukemia cell line HL-60. , 1984, Blood.

[47]  T. Barratt,et al.  Haemolytic-uraemic syndrome: an analysis of prognostic features. , 1983, Archives of disease in childhood.

[48]  J. Klock,et al.  Isolation and chemical characterization of neutral glycosphingolipids of human neutrophils. , 1980, The Journal of biological chemistry.

[49]  P. Vincent.  Granulocyte kinetics in health and disease. , 1977, Clinics in haematology.

[50]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[51]  S. Cutillo.  [Hemolytic-uremic syndrome]. , 1973, La Pediatria.

[52]  Athens Jw.  Granulocyte kinetics in health and disease. , 1969 .